BBA
NTLA icon

Baker Bros. Advisors’s Intellia Therapeutics NTLA Stock Holding History

Baker Bros. Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7M Buy
+930,232
New +$13M 0.08% 62
2025
Q4 		– Sell
-2,746,674
Closed -$47.4M – 94
2025
Q3 		$47.4M Buy
2,746,674
+71,000
+3% +$874K 0.34% 29
2025
Q2 		$25.1M Buy
2,675,674
+2,031,558
+315% +$16.7M 0.24% 33
2025
Q1 		$4.58M Hold
644,116
– – 0.05% 60
2024
Q4 		$7.51M Buy
+644,116
New +$10.1M 0.08% 61
2021
Q1 		– Sell
-111,296
Closed -$6.05M – 129
2020
Q4 		$6.05M Sell
111,296
-10,942
-9% -$397K 0.02% 88
2020
Q3 		$2.43M Sell
122,238
-6,300
-5% -$131K 0.01% 99
2020
Q2 		$2.7M Hold
128,538
– – 0.01% 93
2020
Q1 		$1.57M Hold
128,538
– – 0.01% 95
2019
Q4 		$1.89M Hold
128,538
– – 0.01% 85
2019
Q3 		$1.72M Hold
128,538
– – 0.01% 88
2019
Q2 		$2.1M Hold
128,538
– – 0.01% 85
2019
Q1 		$2.19M Hold
128,538
– – 0.01% 78
2018
Q4 		$1.75M Sell
128,538
-64,000
-33% -$1.19M 0.01% 76
2018
Q3 		$5.51M Sell
192,538
-354,384
-65% -$10.3M 0.04% 69
2018
Q2 		$15M Sell
546,922
-286,873
-34% -$6.95M 0.11% 50
2018
Q1 		$17.6M Sell
833,795
-311,658
-27% -$7.66M 0.15% 44
2017
Q4 		$22M Buy
1,145,453
+83,333
+8% +$1.92M 0.19% 43
2017
Q3 		$26.4M Hold
1,062,120
– – 0.21% 32
2017
Q2 		$17M Hold
1,062,120
– – 0.15% 36
2017
Q1 		$15M Hold
1,062,120
– – 0.12% 37
2016
Q4 		$13.9M Hold
1,062,120
– – 0.14% 40
2016
Q3 		$18.1M Hold
1,062,120
– – 0.16% 37
2016
Q2 		$22.7M Buy
+1,062,120
New +$28.3M 0.24% 31

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Baker Bros. Advisors's NTLA Position: Q2 2026 in Review

Baker Bros. Advisors opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 930,232 shares worth $15.7M. The stake represents 0.08% of the portfolio and ranks #62 among its holdings. This is a return to the name: Baker Bros. Advisors previously reported a position in NTLA as recently as Q3 2025.

Baker Bros. Advisors first reported a position in NTLA in Q2 2016 and has held it in 24 quarters since. The position peaked at $47.4M in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Baker Bros. Advisors held 930,232 shares of Intellia Therapeutics worth $15.7M as of Q2 2026.
  • Intellia Therapeutics was a new Baker Bros. Advisors position in Q2 2026.
  • Intellia Therapeutics made up 0.08% of Baker Bros. Advisors's portfolio in Q2 2026, its #62 holding.
  • Baker Bros. Advisors first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 24 quarters since.
  • Baker Bros. Advisors's Intellia Therapeutics position peaked at $47.4M in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.